Report

The infectious disease diagnostics market is expected to grow from US$ 38.366 billion in 2022 to US$ 59.954 billion by 2030; it is anticipated to register a CAGR of 5.7% from 2022 to 2030. The growing incidence of infectious diseases across the world and rising application of diagnostics in veterinary infectious diseases bolster the infectious disease diagnostics market size. However, an inadequate reimbursement scenario hinders the infectious disease diagnostics market growth.

Rising Incidence of Infectious Diseases Drive Infectious Disease Diagnostics Market Growth

Fungi, viruses, parasites, bacteria, and toxic products are among the infectious agents that can cause infectious diseases. Public health is adversely affected by infectious diseases, causing morbidity, mortality, and economic burdens. Rising incidence of infectious diseases propels the requirement for accurate and timely diagnosis to form the basis for effective disease management, treatment, and prevention. Diagnosing and monitoring multiple infections and diseases, including hepatitis C, HIV, tuberculosis, human papillomavirus, and sexually transmitted infections (STIs), and infectious disease outbreaks can be performed using molecular diagnostics techniques, laboratory-based assays, and point-of-care tests. According to the Centers for Disease Control and Prevention (CDC), ~10.2 million people visited physician offices for the treatment of infectious and parasitic diseases in African countries every year. According to an article published in the National Library of Medicine (NLM) in 2021, infectious diseases are a major concern in most African countries due to high disease burden and limited healthcare resources. More than 200 pathogens can cause fever in Nigeria, one of the most common reasons for visiting a healthcare facility. According to the World Health Organization (WHO), ~58 million people across the world suffer from chronic hepatitis C infection, and ~1.5 million new infections are diagnosed every year. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, ~36 million people were adults, and about 1.7 million were children aged 0-14 years. Also, ~1.5 million new HIV cases were reported globally in 2020.

According to WHO, tuberculosis (TB) is the 13th leading cause of death across the world, and it is the second leading infectious disease that leads to death after COVID-19. According to the WHO, 1.5 million deaths were caused by TB in 2020. In 2020, WHO projected that 10 million people had TB across the world, Furthermore, in 2020, 30 countries with high TB burdens accounted for 86% of new TB cases. Eight countries make up two-thirds of the total cases of TB, with India at the forefront, followed by China, the Philippines, Indonesia, Nigeria, Pakistan, Bangladesh, and South Africa. Thus, the upsurging incidence of infectious diseases bolsters the need for infectious disease diagnostic technologies, such as microbial culture, hemagglutination inhibition tests, and enzyme-linked immunosorbent assays (ELISA).

The report segments the infectious disease diagnostics market as follows:

The infectious disease diagnostics market, by product, is segmented into kits & reagents, instruments, and software & services. The infectious disease diagnostics market, by technology, is segmented into biosensor-based, immunodiagnostics, molecular-based diagnostic, clinical biology, and others. The market for the immunodiagnostics segment is further segmented into enzyme-linked immunosorbent assay, western blotting analysis, and immunofluorescence assay. The market for the molecular-based diagnostic techniques segment is further segmented into polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, next generation sequencing, DNA microarrays, and others. The infectious disease diagnostics market, by application type, is bifurcated into point-of-care testing and laboratory testing. The infectious disease diagnostics market, by testing type, is bifurcated into human testing and veterinary testing. The market for the human testing segment is further segmented into HIV, Hepatitis, HAIs, HPV, tuberculosis, influenza, and others. The infectious disease diagnostics market, by end user, is segmented into diagnostic laboratories, hospitals and clinics, research institutes, homecare settings, and others. Based on geography, the infectious disease diagnostics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Product-Based Insights

The infectious disease diagnostics market, by product, is segmented into kits & reagents, instruments, and software & services. In 2022, the kits & reagents segment held the largest share of the market. However, the market for the software & services segment is expected to grow at the fastest rate during 2022-2030.

Regional-Based Insights

Based on geography, the infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the largest contributor to the growth of the global infectious disease diagnostics market. Asia Pacific is expected to register the highest CAGR in the infectious disease diagnostics market during 2022-2030. The infectious diseases diagnostics market growth in the US is primarily driven by the increasing prevalence of infectious diseases, rising geriatric population, and growing number of product launches by key players.

Abbott Laboratories, Bruker Corp, Cardinal Health, F. Hoffmann-La Roche Ltd, Trinity Biotech Plc, Danaher Corp, Bio-Rad Laboratories Inc, AccuBioTech Co Ltd, ACON Laboratories, and DiaSorin SpA are among the prominent players operating in the infectious disease diagnostics market. These companies focus on new product launches and geographic expansions to meet the growing consumer demand across the world and increase their product range in specialty portfolios. Their global presence allows them to serve a large base of customers, subsequently facilitating market expansion.

A few of the major primary and secondary sources referred to while preparing the report on the infectious disease diagnostics market are the World Health Organization (WHO), the US Census Bureau, The Journal for Infectious Diseases, International Journal of Infectious Diseases, and CDC, among others.